fda crackdown on compounded semaglutide is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified On February 2, 2026, Pope

Financial Times reported this week that Lilly and Novo, the manufacturers of all four GLP-1 drugs commonly used for obesity therapy, are spending $3.5 billion this year to purchase smaller companies with promising anti-obesity therapies

GLP-1 Medical Weight Loss Support GoalBMI Wellness also offers physician-supervised medical weight loss programs that may include GLP-1 and GIP treatment options for appetite control and long-term weight management support

A 2025 article in Nutrition & Diabetes describes it as a construct related to food cue reactivity, meaning the sights, smells, emotions, and routines that can trigger food-seeking thoughts

After injecting, release the skin fold and withdraw the needle